A phase I, open-label, dose-escalation study investigating a low-density lipoprotein receptor-related protein (LRP) 5/6 inhibitor, BI 905677, in patients with advanced solid tumors.

被引：0
|
作者：
Elez, Elena [1 ]
Lenz, Heinz-Josef [2 ]
de Jonge, Maja [3 ]
Yaeger, Rona [4 ]
Doi, Toshihiko [5 ]
Pronk, Linda [6 ]
Teufel, Michael [7 ]
Marzin, Kristell [8 ]
Tabernero, Josep [1 ]
机构：
[1] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[3] Erasmus Med Ctr Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Mem Sloan Kettering Canc Ctr, New York, NY USA
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Boehringer Ingelheim Espana SA, Clin Dev Oncol, Madrid, Spain
[7] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[8] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT514
引用
收藏
页数：2
相关论文
共 50 条
  • [11] A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors
    Gordon, Michael S.
    Mendelson, David S.
    Gross, Mitchell
    Uttenreuther-Fischer, Martina
    Ould-Kaci, Mahmoud
    Zhao, Yihua
    Stopfer, Peter
    Agus, David B.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (02) : 409 - 416
  • [12] A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.
    Kristeleit, Rebecca Sophie
    Shapiro, Geoffrey
    LoRusso, Patricia
    Infante, Jeffrey R.
    Flynn, Michael
    Patel, Manish R.
    Tolaney, Sara M.
    Hilton, John Frederick
    Calvert, Alan Hilary
    Giordano, Heidi
    Isaacson, Jeffrey D.
    Borrow, Jennifer
    Allen, Andrew R.
    Jaw-Tsai, Sarah S.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [13] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Frederik Marmé
    Carlos Gomez-Roca
    Kristina Graudenz
    Funan Huang
    John Lettieri
    Carol Peña
    Zuzana Jirakova Trnkova
    Jan Eucker
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 727 - 737
  • [14] Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors
    Marme, Frederik
    Gomez-Roca, Carlos
    Graudenz, Kristina
    Huang, Funan
    Lettieri, John
    Pena, Carol
    Trnkova, Zuzana Jirakova
    Eucker, Jan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (04) : 727 - 737
  • [15] Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors.
    Daniels, G. A.
    Carson, W. E.
    Mita, A. C.
    Kendra, K. L.
    Rahimy, M. H.
    Inman, D. W.
    Appleman, J. R.
    Freddo, J. L.
    McNeel, D. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [16] Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Hamid, Omid
    Shum, Elaine
    Wise, David R.
    Balar, Arjun Vasant
    Weber, Jeffrey S.
    LoRusso, Patricia
    Shafi, Saba
    Rimm, David L.
    Tolcher, Anthony W.
    Basudhar, Debashree
    Dujka, Melanie Elizabeth
    Heller, Kevin N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [17] A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors
    Molife, L. Rhoda
    Dean, Emma Jane
    Blanco-Codesido, Montserrat
    Krebs, Matthew G.
    Brunetto, Andre T.
    Greystoke, Alastair Peter
    Daniele, Gennaro
    Lee, Lucy
    Kuznetsov, Galina
    Myint, Khin Than
    Wood, Karen
    de las Heras, Begona
    Ranson, Malcolm Richard
    CLINICAL CANCER RESEARCH, 2014, 20 (24) : 6284 - 6294
  • [18] A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Janku, Filip
    Tian, Linjie
    Luke, Jason J.
    Shum, Elaine
    Shin, John
    Weiss, Ido
    Liu, Linda N.
    Files, Dallas
    Langermann, Solomon
    Myint, Han
    Bilusic, Marijo
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [19] A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors
    Spigel, D. R.
    Wang, J. S.
    Pronk, L.
    Muskens, B.
    Teufel, M.
    Bashir, B.
    Burris, H.
    ESMO OPEN, 2024, 9 (11)
  • [20] A phase I, open label, multicenter dose escalation study of AZD2811 nanoparticle in patients with advanced solid tumors.
    Johnson, Melissa Lynne
    Cosaert, Jan G. C. E.
    Falchook, Gerald Steven
    Jones, Suzanne Fields
    Strickland, Donald
    Greenlees, Carol
    Charlton, Julie
    MacDonald, Alexander
    Overend, Philip
    Adelman, Carrie
    Burris, Howard A.
    Pease, Elizabeth J.
    Patel, Gargi Surendra
    Wang, Judy Sing-Zan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345